ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years
Alberto Larghi
Matched on ORCID iD 0000-0001-7131-3686; OpenAlex author ID A5048095559. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 60
2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper
Papers 12
- The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration. Co-author DOI 10.1186/s13046-024-03263-w↗
- Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
- Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
- Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04733-z↗
- Endoscopic Ultrasound Biliary Drainage in Pancreatic Cancer. Last author DOI 10.15403/jgld-4922↗
- Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and a promising therapeutic target Co-author DOI 10.21203/rs.3.rs-2095432/v1↗
- Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response. Co-author DOI 10.3389/fmed.2021.793144↗
- Endoscopic ultrasound-guided gallbladder drainage in pancreatic cancer and cholangitis: A case report. Co-author DOI 10.4253/wjge.v12.i11.488↗
- EUS-guided radiofrequency ablation of the celiac axis in pancreatic cancer: Is money worth the pain? Co-author DOI 10.1016/j.gie.2018.08.048↗
- Echoendoscopic ethanol ablation of tumor combined with celiac plexus neurolysis in patients with pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.13478↗
- Early onset pancreatic cancer: risk factors, presentation and outcome. Co-author DOI 10.1016/j.pan.2015.01.013↗
- Interobserver agreement and accuracy of preoperative endoscopic ultrasound-guided biopsy for histological grading of pancreatic cancer. Co-author DOI 10.1055/s-0034-1390912↗
Closest collaborators
The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Antonio Agostini · 4 shared papers, 2021–2025 · strength 0.59
- Paper The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylatio… DOI 10.1186/s13046-024-03263-w↗
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Geny Piro · 4 shared papers, 2021–2025 · strength 0.59
- Paper The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylatio… DOI 10.1186/s13046-024-03263-w↗
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Giampaolo Tortora · 4 shared papers, 2021–2025 · strength 0.59
- Paper The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylatio… DOI 10.1186/s13046-024-03263-w↗
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Carmine Carbone · 4 shared papers, 2021–2025 · strength 0.59
- Paper The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylatio… DOI 10.1186/s13046-024-03263-w↗
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Vincenzo Corbo · 3 shared papers, 2022–2025 · strength 0.47
- Paper The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylatio… DOI 10.1186/s13046-024-03263-w↗
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Mihai Rimbaș · 2 shared papers, 2019–2023 · strength 0.42
- Giuseppe Quero · 3 shared papers, 2021–2023 · strength 0.39
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Paper Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms… DOI 10.3389/fmed.2021.793144↗
- Sergio Alfieri · 3 shared papers, 2021–2023 · strength 0.39
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Paper Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms… DOI 10.3389/fmed.2021.793144↗
- Guido Costamagna · 4 shared papers, 2015–2021 · strength 0.29
- Paper Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms… DOI 10.3389/fmed.2021.793144↗
- Paper Echoendoscopic ethanol ablation of tumor combined with celiac plexus neurolysis in patients with pancreatic adenocarcin… DOI 10.1111/jgh.13478↗
- Paper Interobserver agreement and accuracy of preoperative endoscopic ultrasound-guided biopsy for histological grading of pa… DOI 10.1055/s-0034-1390912↗
- Alessia Caggiano · 2 shared papers, 2022–2023 · strength 0.27
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Kar Wai Lau · 1 shared paper, 2023 · strength 0.26
- Silvia Malatesta · 1 shared paper, 2025 · strength 0.20
- Danilo Ranieri · 1 shared paper, 2025 · strength 0.20
- Chiara Cencioni · 1 shared paper, 2025 · strength 0.20
- Francesco Spallotta · 1 shared paper, 2025 · strength 0.20
- Lívia Archibugi · 2 shared papers, 2015–2024 · strength 0.17
- Gabriele Capurso · 2 shared papers, 2015–2024 · strength 0.17
- Stefano Francesco Crinò · 1 shared paper, 2019 · strength 0.16
- Francesco De Sanctis · 1 shared paper, 2023 · strength 0.13
- Giuseppe Malleo · 1 shared paper, 2024 · strength 0.13
- Valentina Arcangeli · 1 shared paper, 2024 · strength 0.13
- Erica Secchettin · 1 shared paper, 2024 · strength 0.13
- Fabio Casciani · 1 shared paper, 2024 · strength 0.13
- Riccardo Casadei · 1 shared paper, 2024 · strength 0.13
- Marta Puzzono · 1 shared paper, 2024 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.